Literature DB >> 24493387

Ovarian response to controlled ovarian hyperstimulation in women with cancer is as expected according to an age-specific nomogram.

Marta Devesa1, Francisca Martínez, Buenaventura Coroleu, Ignacio Rodríguez, Clara González, Pedro Nolasco Barri.   

Abstract

PURPOSE: To evaluate the ovarian response to controlled ovarian hyperstimulation (COH) in cancer patients according to an age-specific nomogram for the number of retrieved oocytes.
METHODS: Retrospective observational study carried out in a University affiliated fertility clinic. Forty-eight patients with cancer underwent ovarian stimulation for oocyte cryopreservation. An age - specific nomogram for the number of retrieved oocytes was built with 1536 IVF cycles due to male factor exclusively, oocyte donation and age related fertility preservation. The number of oocytes retrieved in cancer patients was compared to the expected response according to the nomogram using the Z-score.
RESULTS: The mean number of total retrieved oocytes in patients with cancer was 14.04 ± 8.83. After applying the Z-score to compare the number of retrieved oocytes between women with cancer and the expected response according to the age-specific nomogram, we did not observe a statistically significant difference (Z-score 0.23; 95 % CI [-0.13-0.60]). CONCLUSION(S): According to our results, patients with cancer exhibit an ovarian response as expected by age. Despite the limitation of the sample size, the obtained results should encourage oncologists for early referral of women with cancer to fertility specialists.

Entities:  

Mesh:

Year:  2014        PMID: 24493387      PMCID: PMC4016366          DOI: 10.1007/s10815-014-0183-6

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  29 in total

1.  Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.

Authors:  B C Fauser; D de Jong; F Olivennes; H Wramsby; C Tay; J Itskovitz-Eldor; H G van Hooren
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 2.  Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis.

Authors:  Shevach Friedler; Onder Koc; Yariv Gidoni; Arieh Raziel; Raphael Ron-El
Journal:  Fertil Steril       Date:  2011-11-10       Impact factor: 7.329

3.  Effects of malignancies on the gonadal function.

Authors:  Togas Tulandi; Hananel Holzer
Journal:  Fertil Steril       Date:  2012-05-24       Impact factor: 7.329

4.  Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment.

Authors:  Javier Domingo; Vicente Guillén; Yanira Ayllón; María Martínez; Elkin Muñoz; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Fertil Steril       Date:  2012-01-28       Impact factor: 7.329

5.  Response to ovarian stimulation in patients facing gonadotoxic therapy.

Authors:  Lauren N C Johnson; Katherine E Dillon; Mary D Sammel; Brenda L Efymow; Monica A Mainigi; Anuja Dokras; Clarisa R Gracia
Journal:  Reprod Biomed Online       Date:  2013-01-19       Impact factor: 3.828

6.  Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy.

Authors:  Mausumi Das; Fady Shehata; Anwar Moria; Hananel Holzer; Weon-Young Son; Togas Tulandi
Journal:  Fertil Steril       Date:  2011-05-14       Impact factor: 7.329

Review 7.  Oocyte cryopreservation as a fertility preservation measure for cancer patients.

Authors:  Nicole Noyes; Jaime M Knopman; Katherine Melzer; M Elizabeth Fino; Brooke Friedman; Lynn M Westphal
Journal:  Reprod Biomed Online       Date:  2010-11-24       Impact factor: 3.828

8.  Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment.

Authors:  Anwar Moria; Mausumi Das; Fady Shehata; Hananel Holzer; Weon-Young Son; Togas Tulandi
Journal:  Fertil Steril       Date:  2011-01-14       Impact factor: 7.329

Review 9.  Ovarian stimulation in cancer patients.

Authors:  Hakan Cakmak; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2013-05       Impact factor: 7.329

10.  Oocyte cryostorage to preserve fertility in oncological patients.

Authors:  Alberto Revelli; Emanuela Molinari; Francesca Salvagno; Luisa Delle Piane; Elisabetta Dolfin; Simona Ochetti
Journal:  Obstet Gynecol Int       Date:  2012-01-15
View more
  5 in total

1.  Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment.

Authors:  M M Dolmans; S Hollanders de Ouderaen; D Demylle; C Pirard
Journal:  J Assist Reprod Genet       Date:  2015-07-15       Impact factor: 3.412

2.  COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.

Authors:  Elisa Malacarne; Marta Devesa; Francisca Martinez; Ignacio Rodriguez; Buenaventura Coroleu
Journal:  J Assist Reprod Genet       Date:  2020-09-18       Impact factor: 3.412

3.  Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience.

Authors:  Eden R Cardozo; Alexcis P Thomson; Anatte E Karmon; Kristy A Dickinson; Diane L Wright; Mary E Sabatini
Journal:  J Assist Reprod Genet       Date:  2015-01-18       Impact factor: 3.412

4.  Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.

Authors:  Charlotte Sonigo; Marjorie Comtet; Solene Duros; Christophe Sifer; Nathalie Sermondade; Michaël Grynberg
Journal:  J Assist Reprod Genet       Date:  2017-10-06       Impact factor: 3.412

5.  Oocyte and embryo cryopreservation before gonadotoxic treatments: Principles of safe ovarian stimulation, a systematic review.

Authors:  Meghan Ch Ozcan; Victoria Snegovskikh; G David Adamson
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.